Gemtuzumab ozogamicin, mitoxantrone, and etoposide in newly diagnosed acute myeloid leukemia patients with persistent leukemia after a course of induction therapy

被引：0
|
作者：
Michael Boyiadzis
Robert L. Redner
Anastasios Raptis
Jing-Zhou Hou
Mounzer Agha
Kenneth A. Foon
机构：
[1] University of Pittsburgh Cancer Institute,Division of Hematology
来源：
Annals of Hematology | 2011年 / 90卷
关键词：
Acute Myeloid Leukemia; Complete Remission; Etoposide; Anthracycline; Cytarabine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：733 / 735
页数：2
相关论文
共 50 条
  • [21] Efficacy of mitoxantrone and etoposide in patients with acute myeloid leukemia refractory to initial standard induction therapy
    Sehgal, Rajesh
    McHayleh, Wassim
    Natale, James
    Raptis, Anastasios
    Agha, Mounzer
    Redner, Robert L.
    Richard, Gene
    Welsh, Ann
    Foon, Kenneth A.
    Boyiadzis, Michael
    BLOOD, 2007, 110 (11) : 164B - 164B
  • [22] Trial-in-Progress: A Phase 2 Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Acute Myeloid Leukemia That Persisted after the 1st Induction Regimen
    Lontos, Konstantinos
    Redner, Robert L.
    Agha, Mounzer
    Raptis, Anastasios
    Hou, Jing-Zhou
    Farah, Rafic J.
    Im, Annie
    Dorritie, Kathleen
    Sehgal, Alison R.
    Rossetti, James M.
    Normolle, Daniel
    Boyiadzis, Michael M.
    BLOOD, 2022, 140 : 6145 - 6146
  • [23] Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin
    Cowan, Andrew J.
    Laszlo, George S.
    Estey, Elihu H.
    Walter, Roland B.
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2013, 18 : 1312 - 1335
  • [24] Comparative Efficacy and Safety of Gemtuzumab Ozogamicin (GO) Plus Daunorubicin-Cytarabine Combination and Comparators As Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia
    Ashaye, Ajibade
    Khankhel, Zarmina S.
    Xu, Yingxin
    Fahrbach, Kyle
    Mokgokong, Ruth
    Orme, Michelle
    Lang, Kathryn
    Cappelleri, Joseph C.
    Mamolo, Carla M.
    BLOOD, 2017, 130
  • [25] A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
    Petersdorf, Stephen H.
    Kopecky, Kenneth J.
    Slovak, Marilyn
    Willman, Cheryl
    Nevill, Thomas
    Brandwein, Joseph
    Larson, Richard A.
    Erba, Harry P.
    Stiff, Patrick J.
    Stuart, Robert K.
    Walter, Roland B.
    Tallman, Martin S.
    Stenke, Leif
    Appelbaum, Frederick R.
    BLOOD, 2013, 121 (24) : 4854 - 4860
  • [26] Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia
    Akihiro Takeshita
    International Journal of Hematology, 2013, 97 : 703 - 716
  • [27] Gemtuzumab ozogamicin (Mylotarg®) as primary induction therapy for elderly patients with acute myeloid leukemia:: A phase II trial
    Kujawski, LA
    Gartner, EM
    Ryan, I
    Griffith, K
    Erba, HP
    BLOOD, 2004, 104 (11) : 210B - 210B
  • [28] Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia.
    Stadtmauer E.A.
    Current Oncology Reports, 2002, 4 (5) : 375 - 380
  • [29] Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia
    Takeshita, Akihiro
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2013, 97 (06) : 703 - 716
  • [30] Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia in adults
    Goldenson, Benjamin H.
    Goodman, Aaron M.
    Ball, Edward D.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (07) : 849 - 862
12345